Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-200 with or without cetrelimab versus intravesical BCG in BCG-naive high-risk non-muscle invasive bladder cancer
jRCT2031230220Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial in bladder cancer and non-muscle-invasive bladder cancer (NMIBC) comparing TAR-200 + cetrelimab, Bacillus Calmette-Guerin and TAR-200 alone (3 arms). Primary endpoint: Event-free survival. Started Oct 2023; status: active, not recruiting.
02
Drugs
gemcitabine-releasing intravesical systemcetrelimabbcg vaccine
03
Conditions
bladder cancernon-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on jRCT2031230220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230220.